ecancermedicalscience

Research

Germinal mutations among patients with breast cancer in Colombia: is BRCA3 coming?

27 Feb 2025
Lisa Ximena Rodríguez Rojas, Liliana Doza Martínez, Jorge Andrés Olave Rodríguez, Sandra Eliana Murillo Rusynke, Paola Andrea Pérez Castellano, David Alexander Bolaños Beltrán, Helen Johana Ortiz Rojas, José Antonio Nastasi Catanese

Purpose: Breast cancer is the most common type of cancer in women and accounts for 25% of all cancers worldwide. The mechanisms by which it develops include germline (generally inherited) and somatic mutations. There are six mutations with the highest incidence in the Colombian population, called the Colombia profile, which is associated with the BRCA1 and BRCA2 genes. The aim of this study is to identify germline mutations in individuals with breast cancer, such as BRCA and other genes.

Methods: This study describes the frequency and type of variants in hereditary cancer genes associated with breast cancer detected by the next-generation sequencing of a panel of 111 hereditary cancer genes, including BRCA1 and BRCA2.

Results: This analysis allowed the identification of variants associated with breast cancer in 307 patients from a population in southwestern Colombia, of which 19% had pathogenic and probably pathogenic mutations associated with hereditary cancer. According to the variant classification, it was found that the mutation frequency in BRCA1 was 17%, in BRCA2 was 14% and in the ATM gene was 12%; nevertheless, 57% of mutations were attributed to other genes such as MUTYH, FANCM, FANCA and TP53. Four patients were found to have the mutation c.3450delCAAG in the BRCA1 gene, which is included in the Colombia profile.

Conclusion: In summary, in the Colombian population, there is a great diversity of germline mutations in genes other than BRCA1 and BRCA2 that are associated with breast cancer. Studying mutations and variants of uncertain significance in ATM could improve understanding of how mutations in these genes contribute to cancer and whether ATM should be considered as BRCA3.

Related Articles

Jaden Paltoo, Danusha Vinoraj, Elizaveta Klekovkina, Alyssa Tilly, John Bosco, John Lule, Akosua Agyemang, Maria Chikasema, Selena Kleber, Mary Goombs, Iddi Matovu, Craig Sinclair, Wendy G. Lichtenthal, Lesley Chalklin, Eve Namisango, Gary Rodin
Pablo Companys, Tomas Soule, Mariano Aymar, María Natalia Gandur Quiroga, Rosalía Hinojosa Altamirano, Marcelo Fogtman, Augusto Ferreyra Camacho, Rodrigo Sánchez, Gonzalo Taetti, Gabriela Gatica, Natalia Soto, María Elisa Arroyo, Nicolas Mainardi, Carolina Passarella, Andrea Marchioni, Ignacio Jerez, María Pía Domínguez, Emiliano Menna, Harold Somerville, Ernesto Korbenfeld, Florencia Sarru, Karina Peters, Iván Macharashvili, Federico Losco, Laura Pelagatti Santoni, Mauricio Fernández Lazaro, José Zarba, Mabel Gill, Juan Pablo Sade, Federico Cayol
Gbenro E. Olukiran, Adewumi O. Alabi, Anthonia C. Sowunmi, Babatunde Fadipe, Gbenga O. Popoola, Sunday A. Okinbaloye, Hnin L. Nwe Thein, Ololade Kehinde
Leonardo G Da Fonseca, Duilio Reis da Rocha Filho, Aline Lopes Chagas, Alexandre Jacome, Leila Moreira Beltrao Pereira, Rogerio Alves, Mario Reis Alvares-da-Silva, Mauro Donadio, Ana Paula Victorino, Federico Piñero, Cassia Guedes Leal
Zakayo Ernesti, Emanuel Lugina, Chacha J Mwita, Felister Tupa, Herriethsiah S Noah, John R Ngowi, Charles Wood, Julius Mwaiselage, Salum J Lidenge